Lung cancer is associated with acute ongoing cerebral ischemia: A population-based study.

MRI Magnetic resonance diffusion-weighted imaging acute antithrombotic cerebral infraction ischemic stroke lesions radiology stroke subtypes

Journal

International journal of stroke : official journal of the International Stroke Society
ISSN: 1747-4949
Titre abrégé: Int J Stroke
Pays: United States
ID NLM: 101274068

Informations de publication

Date de publication:
11 Dec 2023
Historique:
pubmed: 18 11 2023
medline: 18 11 2023
entrez: 18 11 2023
Statut: aheadofprint

Résumé

Cerebral microinfarcts (CMIs) are the most common type of brain ischemia; however, they are extremely rare in the general population. CMIs can be detected by magnetic resonance diffusion-weighted imaging (MRI-DWI) only for a very short period of approximately 2 weeks after their formation and are associated with an increased stroke risk and cognitive impairment. We aimed to examine CMI detection rate in patients with lung cancer (LC), which is strongly associated with ischemic stroke risk relative to other cancer types. We used the Clalit Health Services record (representing more than 5 million patients) to identify adults with LC and breast, pancreatic, or colon cancer (non-lung cancer, NLC) who underwent brain magnetic resonance diffusion (MRI) scan within 5 years following cancer diagnosis. All brain MRI scans were reviewed, and CMIs were documented, as well as cardiovascular risk factors. Our cohort contained a total of 2056 MRI scans of LC patients and 1598 of NLC patients. A total of 143 CMI were found in 73/2056 (3.5%) MRI scans of LC group compared to a total of 29 CMI in 22/1598 (1.4%) MRI scans of NLC ( CMIs are common findings in cancer patients, especially in LC patients and therefore might serve as a marker for occult brain ischemia, cognitive decline, and cancer-related stroke (CRS) risk.

Sections du résumé

BACKGROUND AND OBJECTIVES UNASSIGNED
Cerebral microinfarcts (CMIs) are the most common type of brain ischemia; however, they are extremely rare in the general population. CMIs can be detected by magnetic resonance diffusion-weighted imaging (MRI-DWI) only for a very short period of approximately 2 weeks after their formation and are associated with an increased stroke risk and cognitive impairment. We aimed to examine CMI detection rate in patients with lung cancer (LC), which is strongly associated with ischemic stroke risk relative to other cancer types.
METHODS UNASSIGNED
We used the Clalit Health Services record (representing more than 5 million patients) to identify adults with LC and breast, pancreatic, or colon cancer (non-lung cancer, NLC) who underwent brain magnetic resonance diffusion (MRI) scan within 5 years following cancer diagnosis. All brain MRI scans were reviewed, and CMIs were documented, as well as cardiovascular risk factors.
RESULTS UNASSIGNED
Our cohort contained a total of 2056 MRI scans of LC patients and 1598 of NLC patients. A total of 143 CMI were found in 73/2056 (3.5%) MRI scans of LC group compared to a total of 29 CMI in 22/1598 (1.4%) MRI scans of NLC (
DISCUSSION UNASSIGNED
CMIs are common findings in cancer patients, especially in LC patients and therefore might serve as a marker for occult brain ischemia, cognitive decline, and cancer-related stroke (CRS) risk.

Identifiants

pubmed: 37978833
doi: 10.1177/17474930231217670
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17474930231217670

Déclaration de conflit d'intérêts

Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Jonathan Naftali (J)

Department of Neurology, Rabin Medical Center, Petach Tikva, Israel.

Rani Barnea (R)

Department of Neurology, Rabin Medical Center, Petach Tikva, Israel.
Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Ruth Eliahou (R)

Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
Department of Radiology, Rabin Medical Center, Petach Tikva, Israel.

Keshet Pardo (K)

Department of Neurology, Rabin Medical Center, Petach Tikva, Israel.

Assaf Tolkovsky (A)

Department of Neurology, Rabin Medical Center, Petach Tikva, Israel.

Meital Adi (M)

Department of Radiology, Kaplan Medical Center, Rehovot, Israel.

Vadim Hasminski (V)

Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
Department of Radiology, Rabin Medical Center, Petach Tikva, Israel.

Walid Saliba (W)

Department of Community Medicine and Epidemiology, Lady Davis Carmel Medical Center, Haifa, Israel.
Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

Sivan Bloch (S)

Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
Department of Neurology, Lady Davis Carmel Medical Center, Haifa, Israel.

Guy Raphaeli (G)

Department of Neurology, Rabin Medical Center, Petach Tikva, Israel.
Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Avi Leader (A)

Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.
Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah Tikva, Israel.

Eitan Auriel (E)

Department of Neurology, Rabin Medical Center, Petach Tikva, Israel.
Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel.

Classifications MeSH